The 6th International Immunoglobulin Symposium was held in Interlaken, Switzerland, on 26–28 March 2009. It continued the proud tradition of international symposia in Interlaken on immunoglobulins, dating back to the first Symposium in the series in 1981. This high-level scientific meeting, which was made possible by an unrestricted educational grant from CSL Behring, was accredited for Continuing Medical Education (CME) by the European Association of Allergology and Clinical Immunology (EAACI), in agreement with the European Accreditation Council for Continuing Medical Education (EACCME), a European Union of Medical Specialists (UEMS) institution.

The Symposium brought together almost 300 scientists, researchers and clinicians from a broad range of disciplines to share their knowledge and experience in a unique forum. As the Scientific Committee of the Symposium, we were very pleased to assemble an esteemed, respected and distinguished international faculty to present their current data. Poster presentations further facilitated the exchange of experiences and ideas, and stimulated extensive discussion.

Immunoglobulins were the focus of the Symposium, both at the molecular and genetic levels, as well as at the clinical level. The use, or potential use, of immunoglobulin therapy in an ever-increasing number of indications, from immunodeficiencies to autoimmune and inflammatory diseases and beyond, to emerging potential novel uses such as Alzheimer's disease or stroke, and the challenges this may represent, were addressed in detail. The research presentations and discussions revealed many new areas of progress and provided an exciting forum with which to build upon diverse experiences.

The aim of these proceedings is to bring together the knowledge and data presented at the Symposium and disseminate this invaluable information to a larger audience. Each session from the Symposium is covered by one paper, written by the authors and co-chairs.

We would like to thank CSL Behring for their unrestricted financial support, not only of the Symposium itself, but also of this supplement. Most importantly, we thank the faculty members and poster presenters for sharing their data and experiences, and the Symposium delegates for their enthusiastic engagement.


SJ has received funding for advice and work carried out on the scientific committee of the meeting and is chief investigator in a study with CSL Behring. SJ has also acted as a paid consultant for Baxter, Octapharma and BPL. JO has served as a consultant to Baxter Biosciences, CSL Behring, and Talecris Biotherapeutics. SK has declared that he has no conflicts of interest.